# Low-Dose Pioglitazone in Patients With NASH (AIM 2)

Study · id `cardio:ct-nct04501406` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT04501406](<https://clinicaltrials.gov/study/NCT04501406>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT04501406

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 166 participants.

## Technical summary

Registry record NCT04501406. Randomized; quadruple masking; primary purpose treatment. Start 2020-12-15 (actual); primary completion 2027-08-31 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 2
- Enrolled: 166 participants (planned count; ClinicalTrials.gov record NCT04501406, source copy `cardio:ctgov-nct04501406-2025-04-04`, retrieved 2026-10-26)
- Started: 2020-12-15 (actual) (ClinicalTrials.gov record NCT04501406, source copy `cardio:ctgov-nct04501406-2025-04-04`, retrieved 2026-10-26)
- Primary completion: 2027-08-31 (anticipated) (ClinicalTrials.gov record NCT04501406, source copy `cardio:ctgov-nct04501406-2025-04-04`, retrieved 2026-10-26)
- Completion: 2027-08-31 (anticipated) (ClinicalTrials.gov record NCT04501406, source copy `cardio:ctgov-nct04501406-2025-04-04`, retrieved 2026-10-26)
- Countries: United States (ClinicalTrials.gov record NCT04501406, source copy `cardio:ctgov-nct04501406-2025-04-04`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct04501406-2025-04-04`, retrieved 2026-10-26)

## The registry's words

- Brief title: Low-Dose Pioglitazone in Patients With NASH (AIM 2)
- Condition: Type 2 Diabetes Mellitus (T2DM)
- Condition: Nonalcoholic Steatohepatitis
- Intervention (Drug): Pioglitazone
- Intervention (Other): Placebo
- Lead sponsor: University of Florida
- Lead sponsor class: OTHER
- Collaborator: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
- Collaborator class: NIH

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry lists this organization as the lead sponsor: University of Florida (`cardio:org-university-of-florida`)
- Registry lists this organization as a collaborator: National Institute of Diabetes and Digestive and Kidney Diseases (`cardio:niddk`)

## Provenance

Content hash: 9f0d32d2d79ee0f7a8ed52f7091b7a01bc222c214a2b047624f9ce1c4fd6a92c
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
